<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714281</url>
  </required_header>
  <id_info>
    <org_study_id>HD-FX-08-EU</org_study_id>
    <nct_id>NCT04714281</nct_id>
  </id_info>
  <brief_title>Comparison of Clinical Performance and Hemocompatibility of Dialyzers Applied During Post-dilution Online Hemodiafiltration</brief_title>
  <acronym>eMPORA III</acronym>
  <official_title>Comparison of Clinical Performance and Hemocompatibility of Dialyzers Applied During Post-dilution Online Hemodiafiltration - eMPORA III Study (Modified POlysulfone membRAne)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Dr. Schauerte (IDS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the clinical performance and the hemocompatibility profile of different&#xD;
      high-flux dialyzers, all applied during post-dilution online hemodiafiltration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to test whether the hemodialyzer FX CorAL 600 (applied&#xD;
      during post-dilution online hemodiafiltration) is non-inferior to the comparator&#xD;
      hemodialyzers FX CorDiax 600 and xevonta Hi 15 in removing ß2-microglobulin.&#xD;
&#xD;
      The secondary objectives of this study are:&#xD;
&#xD;
        -  To compare the FX CorAL 600 dialyzer with the comparator hemodialyzers FX CorDiax 600&#xD;
           and xevonta Hi 15 regarding their efficacies in removing other uremic toxins.&#xD;
&#xD;
        -  To compare the FX CorAL 600 dialyzer with the comparator hemodialyzers FX CorDiax 600&#xD;
           and xevonta Hi 15 regarding their hemocompatibility profiles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective, open, controlled, cross-over (with randomized treatment sequences), interventional, multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Removal rate of β2-microglobulin</measure>
    <time_frame>t=240 minutes of HDF</time_frame>
    <description>Removal rate of β2-microglobulin will be calculated a primary endpoint in blood samples to evaluate the clinical Performance of the dialyzer FXCorAL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Renal Failure</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Hemodiafiltration HDF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dialyser</intervention_name>
    <description>Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).</description>
    <arm_group_label>Hemodiafiltration HDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Existing informed consent form signed and dated by study patient as well as&#xD;
             investigator/authorized physician&#xD;
&#xD;
          -  The patient is legally competent and able to understand the nature, risks, meaning,&#xD;
             and consequences of the clinical trial and can subsequently declare her/his consent&#xD;
             for participation in the clinical trial (cf. European Medical Device Directive and&#xD;
             corresponding national regulations)&#xD;
&#xD;
          -  Patients with a chronic kidney disease stage 5D (end stage renal disease with a&#xD;
             glomerular filtration rate of 15 ml/min or less) on hemodiafiltration as&#xD;
             extracorporeal renal replacement therapy&#xD;
&#xD;
        Study-specific:&#xD;
&#xD;
          -  On online post-dilution hemodiafiltration (HDF), at least 4 h treatment time thrice&#xD;
             weekly with FX or FX CorDiax dialyzer ≥ 1 month&#xD;
&#xD;
          -  Vascular access (fistula or graft) which enables blood flow rate ≥ 300 ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Any condition which could interfere with the patient's ability to comply with the&#xD;
             study. This decision is at the discretion of the treating physician and relates to the&#xD;
             general stable condition of the patient (e.g. any acute condition, e.g. infection or&#xD;
             mental problem which might give reason for concern etc.)&#xD;
&#xD;
          -  Ongoing participation in an interventional clinical study during the preceding 30 days&#xD;
&#xD;
          -  Previous participation in this study&#xD;
&#xD;
          -  Pregnancy (pregnancy test will be conducted at start and end of study with female&#xD;
             patients aged &lt; 55 years) or lactation period&#xD;
&#xD;
          -  Patient is not able to give informed consent according to the European Medical Device&#xD;
             Directive and corresponding national regulations&#xD;
&#xD;
        Study-specific:&#xD;
&#xD;
          -  Recurrent episodes of vascular access failure characterized by e.g. repeated&#xD;
             cannulation problems or unstable blood flows within the last 2 months prior to study&#xD;
             start (&gt;3 times, respectively)&#xD;
&#xD;
          -  Repeated single needle treatments (&gt;3 times within the last 2 months prior to study&#xD;
             start)&#xD;
&#xD;
          -  Catheter as vascular access&#xD;
&#xD;
          -  Unstable patients (due to e.g. acute intercurrent disease like cardiovascular&#xD;
             infarction, decompensated heart failure, cerebrovascular accident, severe infection,&#xD;
             active malignant disease)&#xD;
&#xD;
          -  Patients with NYHA ≥ 3, COPD (GOLD 2-4), frequent intradialytic symptomatic&#xD;
             hypotension&#xD;
&#xD;
          -  Patients with known or suspected allergy to trial product and related products&#xD;
&#xD;
          -  Patients with known inborn or acquired deficiencies of the innate and/or adaptive&#xD;
             immune system&#xD;
&#xD;
          -  Patients with acute (use within last 4 weeks) and/or chronic immunosuppressive&#xD;
             medication e.g. due to immune-mediated disease including autoimmune diseases,&#xD;
             transplantation, or cancer (oral and systemic corticosteroids, calcineurin and&#xD;
             mTOR-inhibitors, immunosuppressive monoclonal antibodies, cytotoxic chemotherapy)&#xD;
&#xD;
          -  Planned absence from dialysis unit within the 14 weeks of study duration e.g. due to&#xD;
             scheduled hospitalization, holidays or any other reason&#xD;
&#xD;
          -  Active HBV, HCV, HIV, SARS-CoV-2 infection, as well as any other febrile illness&#xD;
&#xD;
          -  Reported SARS-CoV-2 infection with or without symptoms within the 12 weeks before&#xD;
             inclusion into the study&#xD;
&#xD;
          -  Unwillingness to undergo repeated SARS-CoV-2 infection testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Götz Ehlerding, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentrum für Nieren-, Hochdruck- und Stoffwechselerkrankungen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuela Stauss-Grabo, Dr</last_name>
    <phone>+49 6172 609 5248</phone>
    <email>Manuela.Stauss-Grabo@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bettina Griesshaber, Dr</last_name>
    <phone>+49 6172 609 6777</phone>
    <email>Bettina.Griesshaber@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W Ries, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PHV-Dialysezentrum Goslar</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Kempkes-Koch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum für Nieren-, Hochdruck- und Stoffwechselerkrankungen</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G Ehlerding, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PHV Dialysezentrum Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Ziegler, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Hemodiafiltration</keyword>
  <keyword>Renal replacement therapy</keyword>
  <keyword>Dialyzer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

